ストックスクリーナーアプリを入手
4.0666
0.33%
-0.0134
前日終値:
$4.08
開ける：
$4.06
24時間の取引高:
511
Relative Volume:
0.01
時価総額：
$116.48M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
+10.51%
1か月 パフォーマンス:
+31.61%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$4.06
$4.07
1週間の範囲:
$3.5474
$4.12
52週間の値動き範囲:
$2.33
$4.12
Insight Molecular Diagnostics Inc Stock (IMDX) Company Profile
名前
Insight Molecular Diagnostics Inc
セクター
電話
949-409-7600
住所
2 INTERNATIONAL PLAZA DR., SUITE 510, NASHVILLE
IMDX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IMDX
Insight Molecular Diagnostics Inc
|
4.07 | 116.77M | 0 | 0 | 0 | 0.00 |
|
TMO
Thermo Fisher Scientific Inc
|
531.07 | 198.56B | 43.21B | 6.58B | 6.17B | 17.28 |
|
DHR
Danaher Corp
|
208.15 | 147.61B | 24.01B | 3.41B | 4.86B | 4.7082 |
|
IDXX
Idexx Laboratories Inc
|
640.44 | 50.96B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
139.17 | 39.13B | 6.79B | 1.22B | 1.09B | 4.2644 |
|
IQV
Iqvia Holdings Inc
|
205.88 | 34.81B | 15.70B | 1.24B | 2.01B | 6.9036 |
Insight Molecular Diagnostics Inc Stock (IMDX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-28 | 開始されました | Lake Street | Buy |
| 2022-05-24 | ダウングレード | Stephens | Overweight → Equal-Weight |
| 2022-03-14 | ダウングレード | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2022-01-07 | 開始されました | Stephens | Overweight |
| 2022-01-06 | 再開されました | Piper Sandler | Overweight |
| 2021-03-17 | 再開されました | Needham | Buy |
| 2021-01-07 | アップグレード | The Benchmark Company | Speculative Buy → Buy |
| 2020-12-16 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2020-11-30 | 開始されました | BTIG Research | Buy |
| 2020-11-10 | 開始されました | KeyBanc Capital Markets | Overweight |
| 2020-07-30 | 繰り返されました | The Benchmark Company | Speculative Buy |
| 2020-07-01 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2020-06-30 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2020-06-02 | 開始されました | Needham | Buy |
| 2019-02-13 | 開始されました | Piper Jaffray | Overweight |
| 2019-01-29 | アップグレード | Janney | Neutral → Buy |
| 2018-12-19 | 再開されました | Lake Street | Buy |
すべてを表示
Insight Molecular Diagnostics Inc (IMDX) 最新ニュース
Insight Molecular Diagnostics names Steven Tahmooressi as VP, marketing - Medical Buyer
Insight Molecular Diagnostics appoints Steven Tahmooressi as VP of Marketing - Investing.com Nigeria
Imdx welcomes new VP Marketing to prepare for commercial transplant assay launch - MarketScreener
iMDx Welcomes New VP Marketing to Prepare for Commercial Transplant Assay Launch - GlobeNewswire
GraftAssureDx kit launching 2026: iMDx hires Steven Tahmooressi as VP Marketing to lead global rollout - Stock Titan
What earnings margins imply for Insight Molecular Diagnostics Inc. (7OC0) stockQuarterly Trade Review & Long-Term Growth Portfolio Plans - newser.com
Is Insight Molecular Diagnostics Inc. (7OC0) stock included in top ETFsJuly 2025 Patterns & Community Consensus Trade Alerts - newser.com
Is Insight Molecular Diagnostics Inc. (7OC0) stock dividend growth reliable - newser.com
Will Insight Molecular Diagnostics Inc. (7OC0) stock attract long term capital inflowsQuarterly Profit Report & Accurate Technical Buy Alerts - newser.com
Bullish Insight Molecular Diagnostics Insiders Rewarded As Their Investment Rises To US$4.85m - simplywall.st
Insight Molecular Diagnostics Inc.'s (NASDAQ:IMDX) large hedge funds owners must be happy as stock continues to impress, up 12% over the past week - Yahoo Finance
iMDx Reports Kidney Transplant Patient Achieved ‘Immune Reset’ with Novel Therapy and GraftAssure Monitoring - Sahm
Insight Molecular Diagnostics stock rises after transplant study publication - Investing.com
Insight Molecular Says GraftAssure Assay Helped Avoid Overtreatment in Kidney Transplant Patient - MarketScreener
IMDX's GraftAssure Assay Shows Promise in Kidney Transplant Moni - GuruFocus
GraftAssure test helps monitor kidney transplant patient during cancer therapy By Investing.com - Investing.com Nigeria
Imdx reports kidney transplant patient achieved 'immune reset' with novel therapy and GraftAssure monitoring - MarketScreener
Molecular Diagnostics Market Analysis: Trends, Opportunities, and Forecast - newstrail.com
Why Insight Molecular Diagnostics Inc. (7OC0) stock benefits from AI revolutionJuly 2025 Price Swings & Community Trade Idea Sharing Platform - newser.com
Insight Molecular Diagnostics Extends Executive Employment Agreement - TipRanks
Insight Molecular Diagnostics grants stock options to executives and amends employment agreement - Investing.com
What analysts say about Insight Molecular Diagnostics Inc 7OC0 stockContrarian Investment Ideas & Stay Invested. Stay Smart. - earlytimes.in
Lake Street Maintains Insight Molecular Diagnostics(IMDX.US) With Buy Rating, Maintains Target Price $8 - 富途牛牛
Autoimmune Disease Diagnostics Market Size Report, 2034 - Global Market Insights Inc.
Why Insight Molecular Diagnostics Inc. (7OC0) stock fits value portfoliosQuarterly Market Review & Smart Allocation Stock Tips - newser.com
Analysts Are Bullish on Top Healthcare Stocks: Evaxion Biotech (EVAX), Azitra Inc (AZTR) - The Globe and Mail
Molecular Diagnostics in Pharmacogenomics Market to Reach USD - openPR.com
HOLX to Discontinue Fluoroscan InSight FD Soon: Will the Stock Suffer? - TradingView
Insight Molecular Diagnostics (IMDX) Highlights GraftAssur at In - GuruFocus
Analysts’ Top Healthcare Picks: CareDx (CDNA), Semler Scientific (SMLR) - The Globe and Mail
Insight Molecular Diagnostics to Showcase Leadership in - GlobeNewswire
Insight Molecular Diagnostics to Showcase Leadership in Kidney Transplant Management at Conferences in Singapore and Orlando - MarketScreener
Insight Molecular Diagnostics Approves Executive Salary Increases - TipRanks
Co-Diagnostics, Inc. Signs Strategic MOU with Partner in Kingdom of Saudi Arabia to Introduce Co-Dx™ PCR Platform to Middle East - Quantisnow
North America In Vitro Diagnostics (IVD) Market Insights and Future Outlook - openPR.com
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Lake Street Remains a Buy on Insight Molecular Diagnostics (IMDX) - The Globe and Mail
iMDx launches 5,000-patient registry to study transplant rejection test - Investing.com
iMDx launches 5,000-patient registry to study transplant rejection test By Investing.com - Investing.com Nigeria
Insight Molecular Diagnostics (IMDX) Launches New Patient Regist - GuruFocus
IMDX Advances GraftAssureDx Clinical Trial for Transplant Rejection Test - GuruFocus
Insight Molecular Diagnostics Inc (IMDX) 財務データ
Insight Molecular Diagnostics Inc (IMDX) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
0.06%
大文字化:
|
ボリューム (24 時間):